P23 | DARA-VTD AND ASCT+ LENALIDOMIDE LED TO HIGH COMPLETE REIMISSION AND MINIMAL RESIDUAL DISEASE NEGATIVITY RATES BY NGF: A REAL-WORLD STUDY OF THE TUSCAN MYELOMA NETWORK IN 228 PATIENTS
V. Venanzi, S. Ciofini, E. Antonioli, G. Buda et autres
Background. The CASSIOPEIA phase 3 study compared two groups of MM patients eligible for autologous transplantation (TE) by adding the monoclonal antibody daratumumab to standard induction therapy (VTD), consolidation and maintenance for 2 years compared to observation. The study demonstrated a deeper …
it (code pays fourni par la source)
0 citations
Haematologica